# Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

> **NCT00314353** · PHASE2 · TERMINATED · sponsor: **NSABP Foundation Inc** · enrollment: 7 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00314353
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2008-05
- **Final completion:** 2010-06
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study was closed early due to low enrollment and new information regarding the benefit of the study regimen.
- **Last updated:** 2021-10-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00314353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00314353, "Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00314353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*